SCYNEXIS, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
SCYNEXIS, Inc. (SCYX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $0.73 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-04.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-03-04
- SCYNEXIS, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $0.73, a 44.27% decline from fiscal 2024.
- SCYNEXIS, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $1.31, a 1.55% increase from fiscal 2023.
- SCYNEXIS, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $1.29, a 47.77% decline from fiscal 2022.
- SCYNEXIS, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $2.47, a 46.65% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month as first filed |
|---|---|---|
| 2025-12-31 | $0.73 10-K · filed 2026-03-04 | |
| 2024-12-31 | $1.31 10-K · filed 2026-03-04 | |
| 2023-12-31 | $1.29 10-K · filed 2025-03-12 | |
| 2022-12-31 | $2.47 10-K · filed 2024-03-28 | |
| 2021-12-31 | $4.63 10-K · filed 2023-03-31 | |
| 2020-12-31 | $4.83 10-K · filed 2022-03-29 | |
| 2019-12-31 | $7.50 10-K · filed 2021-03-29 | $0.75 10-K · filed 2020-03-11 |
| 2018-12-31 | $0.90 10-K · filed 2020-03-11 | |
| 2017-12-31 | $1.39 10-K · filed 2019-03-14 | |
| 2016-12-31 | $2.57 10-K · filed 2018-03-13 | |
| 2015-12-31 | $4.79 10-K · filed 2017-03-13 | |
| 2014-12-31 | $6.24 10-K · filed 2017-03-13 | |
| 2013-12-31 | $25.09 8-K · filed 2015-10-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |